News and Press releases

The EIC has awarded Oxcia AB with a EIC transition grant of 2.5 million Euros for development of OXC-201.

February 24, 2023 · Press releases

Read article

Oxcia AB publishes Year-End Report for 2022

February 15, 2023 · Press releases

Read article

Data show OXC-201 may be a promising treatment for allergic asthma.

October 21, 2022 · Press releases

Read article

Enrolment completed and recommended phase II dose reached for OXC-101

October 14, 2022 · Press releases

Read article

Oxcia AB is strengthening the organization further

September 6, 2022 · Press releases

Read article

New studies show OXC-101 further improves conventional chemotherapy treatment in Acute Myelom Leukemia (AML)

March 23, 2022 · Press releases

Read article

Oxcia reports positive interim data from clinical phase I study in advanced solid cancers

January 17, 2022 · Press releases

Read article

Oxcia contracts Patheon for manufacturing and further strengthens the organization

· Press releases

Read article